We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+30.37%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$558M
AUM Growth
+$201M
Cap. Flow
+$128M
Cap. Flow %
22.94%
Top 10 Hldgs %
67.51%
Holding
90
New
30
Increased
23
Reduced
7
Closed
26

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$51.2M
2
INDP icon
Indaptus Therapeutics
INDP
+$15M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$9.52M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.24M
5
NVTA
Invitae Corporation
NVTA
+$4.06M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.2M
2
KITE
Kite Pharma, Inc.
KITE
+$7.78M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$5.12M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$4.57M
5
ANAB icon
AnaptysBio
ANAB
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 46.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
51
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.04M 0.19%
71,500
-302,007
-81% -$4.57M
TDOC icon
52
PUT
Teladoc Health
TDOC
$1.21B
$995K 0.18%
+30,000
New +$984K
GKOS icon
53
PUT
Glaukos
GKOS
$10.1B
$990K 0.18%
30,000
+5,900
+24% +$224K
AMAG
54
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$923K 0.17%
+50,000
New +$932K
CBMX
55
DELISTED
CombiMatrix Corporation
CBMX
$839K 0.15%
+111,912
New +$759K
MDXG icon
56
PUT
MiMedx Group
MDXG
$622M
$832K 0.15%
+70,000
New +$1.04M
MNKD icon
57
PUT
MannKind Corp
MNKD
$1.17B
$760K 0.14%
350,000
+317,700
+984% +$498K
LXRX icon
58
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
$492K 0.09%
+40,000
New +$591K
DBVT
59
CALL
DBV Technologies
DBVT
$804M
$382K 0.07%
+900
New +$386K
SIOX
60
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$140K 0.03%
+2,538
New +$428K
OTIC
61
CALL
DELISTED
Otonomy, Inc.
OTIC
$57K 0.01%
+17,500
New +$236K
OTLK icon
62
Outlook Therapeutics
OTLK
$171M
$40K 0.01%
182
– –
ONSIW
63
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$12K ﹤0.01%
96,833
– –
ONSIZ
64
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$5K ﹤0.01%
96,833
– –
ACRS icon
65
Aclaris Therapeutics
ACRS
$772M
– –
-90,000
Closed -$2.44M
ANAB icon
66
AnaptysBio
ANAB
$1.59B
– –
-165,690
Closed -$3.96M
ASMB icon
67
CALL
Assembly Biosciences
ASMB
$503M
– –
-15,417
Closed -$3.82M
CYTK icon
68
PUT
Cytokinetics
CYTK
$10.4B
– –
-40,000
Closed -$484K
EPIX
69
DELISTED
ESSA Pharma
EPIX
– –
-22,100
Closed -$242K
EXEL icon
70
PUT
Exelixis
EXEL
$13.8B
– –
-70,000
Closed -$1.72M
INSM icon
71
PUT
Insmed
INSM
$21.3B
– –
-50,000
Closed -$858K
IOVA icon
72
CALL
Iovance Biotherapeutics
IOVA
$1.93B
– –
-324,000
Closed -$2.38M
MYGN icon
73
PUT
Myriad Genetics
MYGN
$285M
– –
-19,400
Closed -$501K
OMER icon
74
PUT
Omeros
OMER
$909M
– –
-40,000
Closed -$796K
SGMO
75
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-30,000
Closed -$264K
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Acuta Capital Partners held 90 positions worth $558M, up 56% from $357M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Acuta Capital Partners deployed $128M of net new capital in Q3 2017, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 60% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $12.2M trimmed.

  • Acuta Capital Partners's largest Q3 2017 buy was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.
  • Acuta Capital Partners added most to Immunomedics Inc in Q3 2017, an estimated $51.2M increase.
  • Acuta Capital Partners's biggest Q3 2017 reduction was Ascendis Pharma A/S, cutting an estimated $12.2M.
  • Acuta Capital Partners fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $7.78M.
  • Acuta Capital Partners's ten largest holdings make up 68% of its $558M portfolio in Q3 2017.
  • Acuta Capital Partners opened 30 new positions and closed 26 in Q3 2017.
  • Acuta Capital Partners's portfolio value rose 56% quarter-over-quarter to $558M.

Based on Acuta Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.